MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, PALI had -$190K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$190K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-2,868 -5,014
Depreciation
1 2
Non-cash operating lease expense
22 62
Recurring fair value measurements of liabilities
-332 9
Issuance of common stock to vendors
0 0
Write-off of deferred equity issuance costs
0 75
Loss on disposal of property and equipment
0 0
Stock-based compensation and related charges
90 138
Other
61 -
Prepaid and other current assets and other noncurrent assets
519 18
Accounts payable and accrued liabilities
-955 1,210
Accrued compensation and benefits
429 -530
Operating lease liabilities
-24 -66
Net cash used in operating activities
-3,553 -4,150
Payments on insurance financing debt
100 80
Proceeds from issuance of common stock and warrants
0 0
Proceeds from the exercise of warrants
3,908 1
Payment of warrant inducement issuance costs
445 0
Payment of equity issuance costs
0 178
Proceeds from issuance of common stock under employee stock purchase plan
0 3
Shares withheld for payment of employee withholding tax liability
0 0
Net cash provided by financing activities
3,363 -254
Net decrease in cash, cash equivalents and restricted cash
-190 -4,404
Cash and cash equivalents at beginning of period
9,847 -
Cash and cash equivalents at end of period
5,253 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

PALISADE BIO, INC. (PALI)

PALISADE BIO, INC. (PALI)